Associated Papers
KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.
Bambach NE et al.
Frontiers in Oncology, 2025
41573641 (PubMed )
Supplement: Table2.xlsx › Sheet1
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
Lai X et al.
Cancer Medicine, 2023
36325957 (PubMed )
Supplement: CAM4-12-6009-s003.xlsx › Table_S2
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S et al.
Cancer Research, 2019
31416841 (PubMed )
Supplement: 00085472can182086-sup-204856_4_supp_5611122_ptqvbx.docx
Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H et al.
The Biochemical Journal, 2015
NCI-60 whole exome sequencing and pharmacological CellMiner analyses.
Reinhold WC et al.
Plos One, 2014
25032700 (PubMed )
Supplement: pone.0101670.s001.xlsx › Supplementary_Table_1
Select a paper to view details